{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:59Z","timestamp":1793042159488,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Advanced Accelerator Applications, a Novartis Company","award":["Advanced Accelerator Applications, a Novartis Company"],"award-info":[{"award-number":["Advanced Accelerator Applications, a Novartis Company"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07246-7","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:57:41Z","timestamp":1744124261000},"page":"4001-4015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-7902","authenticated-orcid":false,"given":"Mark N.","family":"Gaze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-2880","authenticated-orcid":false,"given":"Daria","family":"Handkiewicz-Junak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Hladun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Sorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6831-1129","authenticated-orcid":false,"given":"Simon","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-1494","authenticated-orcid":false,"given":"Antony","family":"Ceraulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Kluczewska-Galka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-8423","authenticated-orcid":false,"given":"Cristina","family":"G\u00e1mez-Cenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-3975","authenticated-orcid":false,"given":"Lisa J.","family":"States","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"El Khouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Aimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Perraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-4520","authenticated-orcid":false,"given":"Gabor","family":"Kollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Khanshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Blumenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazia","family":"Brouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-1254","authenticated-orcid":false,"given":"Anne-Laure","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"7246_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bjc.2016.408","volume":"116","author":"IJ Diets","year":"2017","unstructured":"Diets IJ, Nagtegaal ID, Loeffen J, de Blaauw I, Waanders E, Hoogerbrugge N, et al. Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition. Br J Cancer. 2017;116:163\u20138. https:\/\/doi.org\/10.1038\/bjc.2016.408","journal-title":"Br J Cancer"},{"key":"7246_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pbc.22559","volume":"56","author":"P Navalkele","year":"2011","unstructured":"Navalkele P, O\u2019Dorisio MS, O\u2019Dorisio TM, Zamba GKD, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975\u20132006. Pediatr Blood Cancer. 2011;56:50\u20137. https:\/\/doi.org\/10.1002\/pbc.22559","journal-title":"Pediatr Blood Cancer"},{"key":"7246_CR3","unstructured":"RARECARENet. Information network on rare cancers. http:\/\/www.rarecarenet.eu\/. Accessed 10 July 2024."},{"key":"7246_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","volume":"17","author":"MR Lee","year":"2019","unstructured":"Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212\u20137.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7246_CR5","doi-asserted-by":"publisher","first-page":"e2251","DOI":"10.1210\/clinem\/dgaa965","volume":"106","author":"A Ebbehoj","year":"2021","unstructured":"Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczyk MG, et al. Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study. J Clin Endocrinol Metab. 2021;106:e2251\u201361. https:\/\/doi.org\/10.1210\/clinem\/dgaa965","journal-title":"J Clin Endocrinol Metab"},{"key":"7246_CR6","doi-asserted-by":"publisher","first-page":"2333794x1986271","DOI":"10.1177\/2333794x19862712","volume":"6","author":"ZA Farooqui","year":"2019","unstructured":"Farooqui ZA, Chauhan A. Neuroendocrine tumors in pediatrics. Glob Pediatr Health. 2019;6:2333794x19862712. https:\/\/doi.org\/10.1177\/2333794x19862712","journal-title":"Glob Pediatr Health"},{"key":"7246_CR7","doi-asserted-by":"publisher","first-page":"936178","DOI":"10.3389\/fendo.2022.936178","volume":"13","author":"MJM Kuo","year":"2022","unstructured":"Kuo MJM, Nazari MA, Jha A, Pacak K. Pediatric metastatic pheochromocytoma and paraganglioma: clinical presentation and diagnosis, genetics, and therapeutic approaches. Front Endocrinol (Lausanne). 2022;13:936178. https:\/\/doi.org\/10.3389\/fendo.2022.936178","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7246_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.18388\/abp.2020_6955","volume":"70","author":"T Stachowicz-Stencel","year":"2023","unstructured":"Stachowicz-Stencel T, Pasikowska N, Synakiewicz A. Pheochromocytoma and paraganglioma in children and adolescents. Acta Biochim Pol. 2023;70:487\u201393. https:\/\/doi.org\/10.18388\/abp.2020_6955","journal-title":"Acta Biochim Pol"},{"key":"7246_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2016-3829","volume":"102","author":"C Pamporaki","year":"2017","unstructured":"Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102:1122\u201332. https:\/\/doi.org\/10.1210\/jc.2016-3829","journal-title":"J Clin Endocrinol Metab"},{"key":"7246_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00247-007-0564-4","volume":"38","author":"G Khanna","year":"2008","unstructured":"Khanna G, O\u2019Dorisio SM, Menda Y, Kirby P, Kao S, Sato Y. Gastroenteropancreatic neuroendocrine tumors in children and young adults. Pediatr Radiol. 2008;38:251\u20139. https:\/\/doi.org\/10.1007\/s00247-007-0564-4","journal-title":"Pediatr Radiol"},{"key":"7246_CR11","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.ejcped.2023.100023","volume":"2","author":"D Orbach","year":"2023","unstructured":"Orbach D, Brecht IB, Corradini N, Bouchoucha Y, Roganovic J, Bourdeaut F, et al. The role of cancer predisposition syndrome in children and adolescents with very rare tumours. EJC Paediatr Oncol. 2023;2:100023. https:\/\/doi.org\/10.1016\/j.ejcped.2023.100023","journal-title":"EJC Paediatr Oncol"},{"key":"7246_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l","volume":"92","author":"M de Jong","year":"2001","unstructured":"de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0,Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628\u201333. https:\/\/doi.org\/10.1002\/1097-0215(20010601)92:5%3C628::aid-ijc1244%3E3.0.co;2-l","journal-title":"Int J Cancer"},{"key":"7246_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389\u2013427. https:\/\/doi.org\/10.1210\/er.2002-0007","journal-title":"Endocr Rev"},{"key":"7246_CR14","unstructured":"Advanced Accelerator Applications. LUTATHERA\u00ae [prescribing information]. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/lutathera.pdf. Accessed 10 July 2024."},{"key":"7246_CR15","unstructured":"Advanced Accelerator Applications. LUTATHERA\u00ae [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf. Accessed 10 July 2024."},{"key":"7246_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"key":"7246_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cen.14106","volume":"91","author":"S Satapathy","year":"2019","unstructured":"Satapathy S, Mittal BR, Bhansali A. \u2018Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis\u2019. Clin Endocrinol (Oxf). 2019;91:718\u201327. https:\/\/doi.org\/10.1111\/cen.14106","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7246_CR18","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/biomedicines11041024","volume":"11","author":"M Hertelendi","year":"2023","unstructured":"Hertelendi M, Belguenani O, Cherfi A, Folitar I, Kollar G, Polack BD. Efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas\/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: a systematic literature review. Biomedicines. 2023;11:1024. https:\/\/doi.org\/10.3390\/biomedicines11041024","journal-title":"Biomedicines"},{"key":"7246_CR19","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50:2486\u2013500. https:\/\/doi.org\/10.1007\/s00259-023-06166-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","volume":"20","author":"RT Casey","year":"2024","unstructured":"Casey RT, Hendriks E, Deal C, Waguespack SG, Wiegering V, Redlich A, et al. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024;20:729\u201348. https:\/\/doi.org\/10.1038\/s41574-024-01024-5","journal-title":"Nat Rev Endocrinol"},{"key":"7246_CR21","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.3390\/cancers14205049","volume":"14","author":"JT Castle","year":"2022","unstructured":"Castle JT, Levy BE, Chauhan A. Pediatric neuroendocrine neoplasms: rare malignancies with incredible variability. Cancers (Basel). 2022;14:5049. https:\/\/doi.org\/10.3390\/cancers14205049","journal-title":"Cancers (Basel)"},{"key":"7246_CR22","doi-asserted-by":"publisher","first-page":"e29056","DOI":"10.1002\/pbc.29056","volume":"68","author":"JH Foster","year":"2021","unstructured":"Foster JH, Sher A, Seghers V, Poston J, Wells D, Delpassand ES, et al. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr Blood Cancer. 2021;68:e29056. https:\/\/doi.org\/10.1002\/pbc.29056","journal-title":"Pediatr Blood Cancer"},{"key":"7246_CR23","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/pbc.25993","volume":"63","author":"S Yesil","year":"2016","unstructured":"Yesil S, Tanyildiz HG, Bozkurt C, Sahin G, Ozgur S, Ozkan E, et al. Challenging management of neuroendocrine tumor with hepatic metastasis and carcinoid heart disease in a child. Pediatr Blood Cancer. 2016;63:1499\u2013500. https:\/\/doi.org\/10.1002\/pbc.25993","journal-title":"Pediatr Blood Cancer"},{"key":"7246_CR24","doi-asserted-by":"publisher","first-page":"1193880","DOI":"10.3389\/fnume.2023.1193880","volume":"3","author":"K Hlongwa","year":"2023","unstructured":"Hlongwa K, Kolade O, Alnabulsi A, Steyn R, Brink A, Prasad V, et al. Case report: peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors. Front Nucl Med. 2023;3:1193880. https:\/\/doi.org\/10.3389\/fnume.2023.1193880","journal-title":"Front Nucl Med"},{"key":"7246_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","volume":"21","author":"M Ilanchezhian","year":"2020","unstructured":"Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol. 2020;21:85. https:\/\/doi.org\/10.1007\/s11864-020-00787-z","journal-title":"Curr Treat Options Oncol"},{"key":"7246_CR26","unstructured":"Society of Nuclear Medicine and Molecular Imaging. Lantheus to discontinue production of Azedra. https:\/\/snmmi.org\/Web\/News\/Articles\/Lantheus-to-Discontinue-Production-of-Azedra.aspx. Accessed 14 August 2024."},{"key":"7246_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1530\/ec-20-0292","volume":"9","author":"SK Jaiswal","year":"2020","unstructured":"Jaiswal SK, Sarathi V, Memon SS, Garg R, Malhotra G, Verma P, et al. 177Lu-DOTATATE therapy in metastatic\/inoperable pheochromocytoma-paraganglioma. Endocr Connect. 2020;9:864\u201373. https:\/\/doi.org\/10.1530\/ec-20-0292","journal-title":"Endocr Connect"},{"issue":"Suppl 1","key":"7246_CR28","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1007\/s00259-019-04486-2","volume":"46","author":"B Cassano","year":"2019","unstructured":"Cassano B, Genovese E, Polito C, Longo M, Donatiello S, Napolitano A, et al. Preliminary dosimetric study with 177-lutetium peptide receptor radionuclide therapy for pediatric patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(Suppl 1):S87. https:\/\/doi.org\/10.1007\/s00259-019-04486-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR29","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.epsc.2020.101463","volume":"58","author":"SV Parelkar","year":"2020","unstructured":"Parelkar SV, Shah RS, Oak SN, Sanghvi BV, Munghate G, Mhaskar SS, et al. Excision of bilateral pheochromocytomas followed by staged resection of neuroendocrine carcinoma of the pancreas. J Pediatr Surg Case Rep. 2020;58:101463. https:\/\/doi.org\/10.1016\/j.epsc.2020.101463","journal-title":"J Pediatr Surg Case Rep"},{"key":"7246_CR30","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.wneu.2020.07.165","volume":"143","author":"W Roll","year":"2020","unstructured":"Roll W, M\u00fcther M, Sporns PB, Zinnhardt B, Suero Molina E, Seifert R, et al. Somatostatin receptor-targeted radioligand therapy in head and neck paraganglioma. World Neurosurg. 2020;143:e391\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2020.07.165","journal-title":"World Neurosurg"},{"key":"7246_CR31","unstructured":"US Food and Drug Administration. FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets. Accessed 10 July 2024."},{"key":"7246_CR32","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43:1802\u201311. https:\/\/doi.org\/10.1007\/s00259-016-3382-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundl\u00f6v","year":"2017","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3678-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K, et al. MIRD pamphlet 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57:151\u201362. https:\/\/doi.org\/10.2967\/jnumed.115.159012","journal-title":"J Nucl Med"},{"key":"7246_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40658-022-00436-4","volume":"9","author":"JC Malcolm","year":"2022","unstructured":"Malcolm JC, Falzone N, Gains JE, Aldridge MD, Mirando D, Lee BQ, et al. Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE. EJNMMI Phys. 2022;9:24. https:\/\/doi.org\/10.1186\/s40658-022-00436-4","journal-title":"EJNMMI Phys"},{"key":"7246_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/s1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/s1470-2045(21)00572-6","journal-title":"Lancet Oncol"},{"key":"7246_CR37","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1007\/s00259-022-05771-3","volume":"49","author":"D Clement","year":"2022","unstructured":"Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, et al. Efficacy and safety of 177Lu\u2013DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. Eur J Nucl Med Mol Imaging. 2022;49:3529\u201337. https:\/\/doi.org\/10.1007\/s00259-022-05771-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR38","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","volume":"54","author":"A Sabet","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, P\u00f6ppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857\u201361. https:\/\/doi.org\/10.2967\/jnumed.112.119347","journal-title":"J Nucl Med"},{"key":"7246_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","volume":"52","author":"JE Gains","year":"2011","unstructured":"Gains JE, Bomanji JB, Fersht NL, Sullivan T, D\u2019Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52:1041\u20137. https:\/\/doi.org\/10.2967\/jnumed.110.085100","journal-title":"J Nucl Med"},{"key":"7246_CR40","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s00259-020-04741-x","volume":"47","author":"JE Gains","year":"2020","unstructured":"Gains JE, Moroz V, Aldridge MD, Wan S, Wheatley K, Laidler J, et al. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020;47:2348\u201357. https:\/\/doi.org\/10.1007\/s00259-020-04741-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7246_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-020-0273-8","volume":"7","author":"A Chicheportiche","year":"2020","unstructured":"Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, Oleinikov K, Meirovitz A, Gross DJ, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7:5. https:\/\/doi.org\/10.1186\/s40658-020-0273-8","journal-title":"EJNMMI Phys"},{"key":"7246_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","volume":"102\u2013103","author":"L Geenen","year":"2021","unstructured":"Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol. 2021;102\u2013103:1\u201311. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.006","journal-title":"Nucl Med Biol"},{"key":"7246_CR43","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.2967\/jnumed.121.262977","volume":"62","author":"N Pandit-Taskar","year":"2021","unstructured":"Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, et al. Dosimetry in clinical radiopharmaceutical therapy of cancer: practicality versus perfection in current practice. J Nucl Med. 2021;62:S60\u201372. https:\/\/doi.org\/10.2967\/jnumed.121.262977","journal-title":"J Nucl Med"},{"key":"7246_CR44","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/0284186x.2017.1378431","volume":"57","author":"M Sandstr\u00f6m","year":"2018","unstructured":"Sandstr\u00f6m M, Garske-Rom\u00e1n U, Johansson S, Granberg D, Sundin A, Freedman N. Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol. 2018;57:516\u201321. https:\/\/doi.org\/10.1080\/0284186x.2017.1378431","journal-title":"Acta Oncol"},{"key":"7246_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40658-021-00422-2","volume":"8","author":"PF Staanum","year":"2021","unstructured":"Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys. 2021;8:78. https:\/\/doi.org\/10.1186\/s40658-021-00422-2","journal-title":"EJNMMI Phys"},{"key":"7246_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2967\/jnumed.121.262069","volume":"63","author":"D Roth","year":"2022","unstructured":"Roth D, Gustafsson J, Warfvinge CF, Sundl\u00f6v A, \u00c5kesson A, Tennvall J, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE. J Nucl Med. 2022;63:399\u2013405. https:\/\/doi.org\/10.2967\/jnumed.121.262069","journal-title":"J Nucl Med"},{"key":"7246_CR47","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.Ccr-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2743","journal-title":"Clin Cancer Res"},{"key":"7246_CR48","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1210\/jcem.74.5.1349024","volume":"74","author":"JC Reubi","year":"1992","unstructured":"Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 1992;74:1082\u20139. https:\/\/doi.org\/10.1210\/jcem.74.5.1349024","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1007\/s00259-025-07344-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07246-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:02:56Z","timestamp":1756886576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07246-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7246"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07246-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00259-025-07344-6","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-025-07344-6","URL":"https:\/\/doi.org\/10.1007\/s00259-025-07344-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines and all applicable regulations. This study was approved by the institutional review board or independent ethics committee at each participating centre (France: Comit\u00e9 de Protection des Personnes Ile-de-France; Poland: Komisja Bioetyczna przy Centrum Onkologii Instytut im. M. Sk\u0142odowskiej Curie; Spain: CEIC Hospital General Universitario Gregorio Mara\u00f1on; UK: London \u2013 Westminster Research Ethics Committee Health Research Authority; USA: Cincinnati Children\u2019s Hospital Medical Center IRB, CHOP Committees for the Protection of Human Subjects and University of Kentucky IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the parent\/legal guardian for adolescents or adolescents signed assent along with parental\/legal guardian consent or co-signed consent with parent\/legal guardian in accordance with local regulations, prior to participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MNG, RH, CS, SW, AC, AK-G, CG-C, LJS and REK have no relevant competing interests to disclose. DH-J has received travel grants and lecture fees from Ipsen, Novartis and Sanofi, and has acted as a consultant and served on advisory boards for Novartis. TWL has received research funding from Bayer and Pfizer, and has acted as a consultant and served on advisory boards for Advanced Microbubbles, AI Therapeutics, Bayer, GSK, ITM Oncologics, Jazz Pharmaceuticals and Massive Bio. RS declares that Novartis paid CDE Dosimetry Services to perform the dosimetry analysis. PA is an employee of Novartis. KP and GK are employees of Advanced Accelerator Applications, a Novartis Company. FK was an employee of Novartis at the time of manuscript development. LB is an employee of and holds stock and share options in Novartis. FB is an employee of and holds share options in Advanced Accelerator Applications, a Novartis Company. A-LG has received lecture fees and consultancy fees from Advanced Accelerator Applications (a Novartis company) and Curium.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}